UC Berkeley Inclusive Data Program Inspires Learners From 30 Countries With the Power of Data & Analytics Using the Pyramid Decision Intelligence Platform
A 4-year public / private partnership between UC Berkeley Haas School of Business – Fisher Center for Business Analytics’ Program Director, Gauthier Vasseur, and Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, today celebrated the milestone of teaching more than 2,000 learners in 30 countries. The Fisher Center’s Alliance for Inclusive AI (AIAI) program provides data & analytics workshops to improve inclusivity and accessibility to analytics. The Step Into Data program uses a combination of in-person and remote learning to reach people who are under-represented in AI, machine learning, and data analytics. The program will soon expand to the Netherlands, France, Georgia, India, and to new locations across the United States.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005099/en/
“It is my pleasure to work with Pyramid Analytics... They are a company genuinely committed to improving access and opportunities in data analytics, investing in these classes for students from around the world. I am constantly in awe of the capabilities of the Pyramid platform. It is a true gamechanger for our industry, providing an intuitive and engaging platform to put the power of analytics into everyone’s hands. I look forward to many more years of partnership together.” Gauthier Vasseur, Executive Director of the Fisher Center for Business Analytics at the University of California, Berkeley, Haas School of Business and Co-President of AIAI (Graphic: Business Wire)
Key Points:
- Pyramid Analytics supports Program Director, Gauthier Vasseur’s, 15-hour Step Into Data workshops through the Fisher Center’s Alliance for Inclusive Artificial Intelligence (AIAI) initiative and Data Wise Academy.
- The Pyramid Decision Intelligence Platform is at the core of the curriculum.
- Pyramid Analytics provides free licenses to program participants.
- AIAI provides opportunities for women, minorities, and other people in underserved communities by providing access to data literacy training and education.
- Vasseur has an extensive background in data, having spent a decade in Silicon Valley with technology companies including Brio, Google, Hyperion, Oracle, and various start-ups in the space.
For more than a decade, Vasseur has worked with business teams and students around the world to help them master data and analytics. He is a leading voice at UC Berkeley for data analytics, building ties with universities, professional associations, and Fortune 500 companies. At The AIAI, Vasseur is a champion for efforts to create a more inclusive space for business analytics, helping connect the benefits of the technology with underserved communities around the world.
The Step Into Data workshop provides hands-on experience with the Pyramid Decision Intelligence Platform. AIAI programs often feature learners who have plateaued in Excel or basic business intelligence (BI) tools and want to learn more. They are walked through the rapid process of preparing and analyzing data on Pyramid’s governed self-service platform. Learners in these workshops can experiment with problems from school or work and strategize solutions using Pyramid. Even when the programs are over, participants can continue to learn and refine their data science skills – accessed via the dedicated Pyramid server at UC Berkeley.
Students receive an array of benefits from the UC Berkeley-Pyramid workshops including developing valuable analytics skills that often provide opportunities for professional advancement. Feedback from learners who have taken the program is consistently positive and many report that they now have the skills to apply decision intelligence to solve problems and drive positive change. Diversity in data and analytics enriches all aspects of the data value chain, bringing different perspectives to problem-solving and decision-making across the business.
Decision Intelligence is the Next Big Data Analytics Innovation
Artificial Intelligence (AI) is an increasingly important analytics technology. But AI to date is limited to highly-trained practitioners, and until now, there has been no easy way to integrate the essential AI components of Data Prep, Business Analytics, and Data Science. Pyramid solutions meet this need: its Decision Intelligence solutions go beyond traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. Pyramid’s platform lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.
In particular, the Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.
Quotes
Omri Kohl , Chief Executive Officer, and Co-Founder, Pyramid Analytics: “The benefits of technology should be available for all. Business intelligence and analytics is a revolutionary and essential field in today’s economy and it should not require a background in data science to make the most of it. At Pyramid, we are opening the door for as many people as possible to make faster, more intelligent decisions with data. It is our honor to partner with Program Director, Gauthier Vasseur, on this endeavor. He is a leading force for good in our industry, helping people and businesses make the world a better place through data.”
Gauthier Vasseur, Executive Director of the Fisher Center for Business Analytics at the University of California, Berkeley, Haas School of Business and Co-President of AIAI: “Data is not important. It’s what you do with it that makes it meaningful. Used in the right way, it has the capacity to change the world, helping reimagine new solutions to the biggest problems we face today. The technology is all there. The problem is far more profound: an economy where people of all ages and backgrounds are held back from using data by a lack of skills.
“I am passionate about using my platform to spread the world about data analytics, empowering people to make faster, more informed decisions with data. At the core of this work is creating a more diverse and equitable business analytics space. DEI is not just something we should do; we must do it. The data analytics chain is still too dominated by the same social groups, with the same limited perspectives when reading an algorithm or a piece of analysis. Diversity of thought brings with it fresh insights, skills, and approaches – driving new and innovative ways of doing things across the business.
“It is my pleasure to work with Pyramid Analytics on this endeavor. They are a company genuinely committed to improving access and opportunities in data analytics, investing in these classes for students from around the world. I am constantly in awe of the capabilities of the Pyramid platform. It is a true gamechanger for our industry, providing an intuitive and engaging platform to put the power of analytics into everyone’s hands. I look forward to many more years of partnership together.”
About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for anyone to make faster, more informed decisions. It provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. The Pyramid Decision Intelligence Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220926005099/en/
Contact information
Media Contact
UK
Alex Izza
Resonance
+44 759 189 9654
pyramidanalytics@resonancecrowd.com
US
Heather Racicot
Resonance
+1 360-632-5616
pyramidanalytics@resonancecrowd.com
Chas Kielt
Vice President of Global Corporate Communications and Partner Marketing, Pyramid Analytics
617.687.3371
chas.kielt@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom